CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 30 enrolled
Drug / intervention
Niacin +1 moredrug
Likely dose
Niacin 1000 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00852969
NCT00852969Phase 4Completed
CompareCT.gov

Does Raising HDL-C With Niacin Improve Endothelial Function in Early CKD?

Tufts Medical Center·interventional·Posted Feb 27, 2009·Updated May 6, 2014

In Brief

A Phase 4 clinical trial evaluating Niacin and Active Placebo for Chronic Kidney Disease. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The purpose of this study is to obtain information on whether raising levels of HDL-cholesterol (the "good" cholesterol) can improve how blood vessels work in kidney disease. This may help us understand the causes leading to high rates of heart disease in kidney disease and also ways to reduce this risk.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Kidney Disease
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 4CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 27, 2009
Enrollment StartAug 1, 2008
Primary CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 17.3 years ago

Interventions

Niacindrug

1000 mg tablets once per day

Active Placebodrug

100 mg Niacin tablets once per day